ATE227133T1 - Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber - Google Patents

Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber

Info

Publication number
ATE227133T1
ATE227133T1 AT95910629T AT95910629T ATE227133T1 AT E227133 T1 ATE227133 T1 AT E227133T1 AT 95910629 T AT95910629 T AT 95910629T AT 95910629 T AT95910629 T AT 95910629T AT E227133 T1 ATE227133 T1 AT E227133T1
Authority
AT
Austria
Prior art keywords
alpha
ifn
pct
treating viral
interferon
Prior art date
Application number
AT95910629T
Other languages
English (en)
Inventor
Graham Russell Foster
Howard Christopher Thomas
Original Assignee
Imperial College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9404379A external-priority patent/GB9404379D0/en
Priority claimed from GB9420340A external-priority patent/GB9420340D0/en
Application filed by Imperial College filed Critical Imperial College
Application granted granted Critical
Publication of ATE227133T1 publication Critical patent/ATE227133T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95910629T 1994-03-07 1995-03-07 Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber ATE227133T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9404379A GB9404379D0 (en) 1994-03-07 1994-03-07 Therapeutic improvement
GB9420340A GB9420340D0 (en) 1994-10-10 1994-10-10 Therapeutic improvement
PCT/GB1995/000488 WO1995024212A1 (en) 1994-03-07 1995-03-07 The use of interferon subtypes in the preparation of medicaments to treat viral infections

Publications (1)

Publication Number Publication Date
ATE227133T1 true ATE227133T1 (de) 2002-11-15

Family

ID=26304449

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95910629T ATE227133T1 (de) 1994-03-07 1995-03-07 Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber

Country Status (10)

Country Link
US (1) US6007805A (de)
EP (1) EP0741577B1 (de)
JP (1) JP4001379B2 (de)
AT (1) ATE227133T1 (de)
AU (1) AU1854695A (de)
DE (1) DE69528751T2 (de)
DK (1) DK0741577T3 (de)
ES (1) ES2186714T3 (de)
PT (1) PT741577E (de)
WO (1) WO1995024212A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (de) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
GB9702021D0 (en) * 1997-01-31 1997-03-19 Imperial College Medicaments
US6436391B1 (en) * 1997-01-31 2002-08-20 Imperial College Of Science, Technology & Medicine Use of interferon (IFN)-α8 and -α14 as vaccine adjuvants
IT1295657B1 (it) * 1997-11-04 1999-05-24 Alfa Wassermann Spa Oligopeptidi antiparalleli e oligopeptidi idrofobicamente complementari, matrici che li contengono e loro uso nella
ES2138565B1 (es) * 1998-05-13 2000-08-16 Inst Cientifico Tecnol Navarra Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
GB9818445D0 (en) * 1998-08-24 1998-10-21 Imp College Innovations Ltd Medicaments
CN100420482C (zh) * 2000-11-03 2008-09-24 精达制药公司 ω干扰素在制备用于治疗丙型肝炎的药物中的用途
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
KR20040053291A (ko) * 2001-11-09 2004-06-23 바이오메디신즈 인코포레이티드 오메가 인터페론을 이용한 질환 치료 방법
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2005046715A1 (ja) * 2003-11-12 2005-05-26 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo 生理活性複合体
PT1711207E (pt) * 2003-12-10 2013-02-13 Medarex Inc Anticorpos alfa interferão e seus usos
JP4896745B2 (ja) 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2007044083A2 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
JPWO2009116491A1 (ja) 2008-03-21 2011-07-21 株式会社林原生物化学研究所 ヒトインターフェロンαサブタイプα８及びその変異蛋白質を特異的に認識するモノクローナル抗体
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
GB201215873D0 (en) 2012-09-05 2012-10-24 Alfacyte Ltd Compositions and methods relating to the treatment of allergy and allergic diseases
GB201404403D0 (en) * 2014-03-12 2014-04-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US11267860B2 (en) 2015-09-15 2022-03-08 ILC Therapeutics, LTD Compositions and methods relating to the treatment of diseases
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657141A5 (de) * 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
GB8303165D0 (en) * 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
JPH02197539A (ja) * 1989-01-26 1990-08-06 Tanaka Kikinzoku Kogyo Kk 装飾品用Ｃｏ含有貴金属材料
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
ATE179330T1 (de) * 1992-02-10 1999-05-15 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute

Also Published As

Publication number Publication date
DK0741577T3 (da) 2003-02-17
PT741577E (pt) 2003-03-31
WO1995024212A1 (en) 1995-09-14
ES2186714T3 (es) 2003-05-16
JP4001379B2 (ja) 2007-10-31
EP0741577A1 (de) 1996-11-13
EP0741577B1 (de) 2002-11-06
DE69528751D1 (de) 2002-12-12
AU1854695A (en) 1995-09-25
JPH09509955A (ja) 1997-10-07
US6007805A (en) 1999-12-28
DE69528751T2 (de) 2003-07-10

Similar Documents

Publication Publication Date Title
ATE227133T1 (de) Verwendung von interferon-alpha 8 subtype zur herstellung von medikamenten zur behandlung von viralinfektionen der leber
ATE254926T1 (de) Verwendung eines consensus-interferons zur reduzierung der nebeneffekte in der interferon behandlung von viralen hepatiten.
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE164067T1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ES2125976T3 (es) Otros derivados de indol con accion antiviral.
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
DE69310528D1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
ATE212845T1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
ATE78824T1 (de) Verwendung von nukleosiden zur herstellung eines medikamentes zur behandlung von krankheiten, die durch einen retrovirus oder den hepatitis-b-virus verursacht werden.
ATE59778T1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
DE69531150D1 (de) Verwendung von biopolymeren zur behandlung der muskeln
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
DE69328102D1 (de) Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE174507T1 (de) Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE155795T1 (de) Verwendung von leukoregulin zur behandlung von mit einem envelope-virus infizierten tier
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
ATE245199T1 (de) Behandlung von influenzavirus-infektion unter verwendung von antiviralen acylierung/palmitylierung von hemagglutinin hemmen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0741577

Country of ref document: EP

REN Ceased due to non-payment of the annual fee